Advanced in Indigestion

Jordi T. Serra-Pueyo

UCL Queen Square Institute Of Neurology
London, ENG, GB 
Advanced in Indigestion
UCL Queen Square Institute Of Neurology
London, ENG, GB 
OverviewLocationsClinical Research

Overview

Jordi Serra-Pueyo practices in London, United Kingdom. Serra-Pueyo is rated as an Advanced expert by MediFind in the treatment of Indigestion. Their top areas of expertise are Irritable Bowel Syndrome (IBS), Indigestion, Gastroparesis, Thrombectomy, and Endoscopy.

Their clinical research consists of co-authoring 145 peer reviewed articles and participating in 2 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, they have co-authored 10 articles and participated in 1 clinical trial in the study of Indigestion.

Locations

UCL Queen Square Institute of Neurology
London, ENG, United Kingdom
Other Locations
Institut Del Cor, Badalona, CT, Spain

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

2 Clinical Trials

Effect of STW5 (Iberogast ®) and STW5-II (Iberogast N®) on Transit and Tolerance of Intestinal Gas
Effect of STW5 (Iberogast ®) and STW5-II (Iberogast N®) on Transit and Tolerance of Intestinal Gas
Enrollment Status: Completed
Publish Date: September 22, 2023
Intervention Type: Drug
Study Drugs: Iberogast®, Iberogast® N
Study Phase: Phase 4
A Phase II, Multicentre, Randomised, Double-blind, Placebo Controlled, Proof of Concept Study of Efficacy and Safety of Rifamycin SV-MMX® 600 mg Tablets Administered Three or Two Times Daily to Patients With Diarrhoea-predominant Irritable Bowel Syndrome (IBS-D)
A Phase II, Multicentre, Randomised, Double-blind, Placebo Controlled, Proof of Concept Study of Efficacy and Safety of Rifamycin SV-MMX® 600 mg Tablets Administered Three or Two Times Daily to Patients With Diarrhoea-predominant Irritable Bowel Syndrome (IBS-D)
Enrollment Status: Completed
Publish Date: January 08, 2021
Intervention Type: Drug
Study Phase: Phase 2
View 1 Less Clinical Trial

145 Total Publications

Reply to: "Bridging Electrophysiology and Digital Health: Microneurography Findings in Long COVID Herald a New Era of AI-Powered Peripheral Nerve Monitoring".
Reply to: "Bridging Electrophysiology and Digital Health: Microneurography Findings in Long COVID Herald a New Era of AI-Powered Peripheral Nerve Monitoring".
Journal: Annals of neurology
Published: December 12, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Serra-Pueyo's expertise for a condition
ConditionClose
      View All 7 Advanced Conditions
      View All 30 Experienced Conditions
      Want to save this expert for later?
      Sign Up
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile